Defining Progression in Metastatic Kidney Cancer
3 Görünümler
• 06/26/23
0
0
gömmek
administrator
Aboneler
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Daha fazla göster
Facebook Yorumları
SORT BY-
En Çok Yorumlananlar
-
Son Yorumlar